Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 97

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part II, Item 2
Chunk 97
---
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

(a)    Sales of Unregistered Securities.

None.

Item 3.    Defaults Upon Senior Securities

None.

Item 4.    Mine Safety Disclosures

None.

Item 5.    Other Information

(a)     None.

(b)    None.

(c)    Insider Trading Arrangements and Policies.

63

Table of Contents

The table below lists the insider trading arrangements adopted or terminated during the third quarter of 2025:Name and Title of Director or OfficerRule 10b5-1 Trading Arrangement(1)Trading Arrangement Adopted or TerminatedDate of Adoption or TerminationDuration of Trading ArrangementAggregate Number of Securities to be Purchased Pursuant to Trading ArrangementAggregate Number of Securities to be Sold Pursuant to Trading ArrangementFrank Mottola SVP, Chief Technology Operations Officer YesAdoptedSeptember 15, 2025January 14, 2026—20,000____________________________________(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).(2)This trading arrangement covers the exercise and sale of stock options, with a portion of such sales limited to an amount reasonably estimated such that the net proceeds from the sale are sufficient to cover the exercise cost and taxes associated with the exercise of the stock options.

Item 6.    Exhibits

The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q:ExhibitNumberDescription10.1††Biogen Collaboration and License Agreement by and among Sage Therapeutics, Inc., Biogen MA Inc. and Biogen International GmbH, dated November 27, 2020 (incorporated by reference to Exhibit 10.30 of Sage Therapeutics, Inc.'s Registration Statement on Form 10-K (File No. 001-36544) filed on February 16, 2023).10.2Side Letter to Biogen Collaboration and License Agreement,, by and among Sage Therapeutics, Inc., Biogen MA Inc. and Biogen International GmbH, dated October 21, 2021 (incorporated by reference to Exhibit 10.4 of Sage Therapeutics, Inc.'s Quarterly Report on Form 10-Q (File No. 001-36544) filed on November 2, 2021). 31.1Certification of Chief Executive